Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DS6051b · 1 trial · 1 indication
Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
| Arm | Type | Description |
|---|---|---|
| DS-6051b | EXPERIMENTAL | DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D. |
| Name | Type | Description |
|---|---|---|
| DS6051b | DRUG | DS-6051b 50 mg and 200 mg capsules for oral administration |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available 2. Part 1 Dose Escalation subjects must meet 1 of the following criteria: * Solid t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
DS6051b is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development, with a completed first-in-human trial evaluating its safety, tolerability, and pharmacokinetics in patients with solid tumors.
DS6051b is being developed by Nuvation Bio Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol NUVB.
DS6051b is in Phase 1 clinical development. A first-in-human study has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities and is still undergoing clinical evaluation.
DS6051b has one completed clinical trial, identified as NCT02279433. This was a first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in patients with solid tumors. The trial enrolled 46 participants in the United States.
DS6051b is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on safety and tolerability, and the drug has not yet received regulatory approval for any indication.